10/29
11:05 pm
imab
Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders
Neutral
Report
Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders
10/29
11:15 am
imab
I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform
Low
Report
I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform
10/28
10:00 am
imab
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB
10/27
10:07 am
imab
I-Mab (NASDAQ:IMAB) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
I-Mab (NASDAQ:IMAB) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
10/27
10:07 am
imab
I-Mab (NASDAQ:IMAB) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
I-Mab (NASDAQ:IMAB) had its "buy" rating reaffirmed by analysts at HC Wainwright.
10/27
08:06 am
imab
I-Mab (NASDAQ:IMAB) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $6.00 price target on the stock.
Low
Report
I-Mab (NASDAQ:IMAB) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $6.00 price target on the stock.
10/24
08:06 am
imab
I-Mab (NASDAQ:IMAB) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $9.00 price target on the stock.
Medium
Report
I-Mab (NASDAQ:IMAB) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $9.00 price target on the stock.
10/23
10:00 am
imab
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB
10/22
12:35 pm
imab
I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025
Low
Report
I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025